Gara Jalqabaatti › Baayyee Ulfaataa › Tennessee
Qorannoo klinikaalii Baayyee Ulfaataa Tennessee keessatti
Qorannoo 25 Baayyee Ulfaataa f Tennessee keessatti hirmaatuu jiru.
Magaalota Tennessee keessatti
Takkalaa qorannoo (Ingiliffa)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Holston Medical Group - Bristol /ID# 282045, Bristol
- New Phase Research & Development /ID# 282131, Knoxville
- Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- M3 Wake Research Chattanooga, Chattanooga
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- LifeDoc Health, Memphis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 8 hanga 18 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- New Phase Research and Development, Knoxville
- Clinical Research Associates Inc, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07794579Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Vanderbilt Health One Hundred Oaks, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 6 hanga 17 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Center Of The Midsouth, Cordova
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06937086A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Franklin
- Research Site, Jackson
- Research Site, Knoxville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Stern Cardiovascular Foundation Inc, Germantown
- Accellacare of Knoxville, Knoxville
- Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
- fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 45 hanga 99 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Memphis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Memphis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Innovative Clinical Research, Clarksville
- Clinical Research Associates, Nashville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Nashville
Namoota walitti qabaa jiraSadarkaa 3Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- DelRicht Research - Thompson's Station, Smyrna
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Ful-2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailea Clinical Site, Memphis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- New Phase Research and Development, Knoxville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chattanooga
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07284875A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Kingsport
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Knoxville
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT07654361Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Holston Medical Group_Bristol, Bristol
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Wax-2026 · NCT07607587A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Knoxville
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 09-Wax-2026 · NCT07142707Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.